Document is current
Any future updates will be listed below
-
Authors
Famula, Jessica
Ferrer, Emilio
Hagerman, Randi J.
Tassone, Flora
Schneider, Andrea
Rivera, Susan M.
Hessl, David https://orcid.org/0000-0002-3460-9805
-
Funding
Funding for this research was provided by:
National Institute of Child Health and Human Development (HD036071, HD02274, HD103526)
National Institute of Mental Health (MH078041)
National Institute of Neurological Disorders and Stroke (NS110100)
National Institute on Aging (AG032115)
- License Information
-
More Information
Article History
Received: 22 October 2021
Accepted: 14 March 2022
First Online: 23 March 2022
Declarations
:
: This study was approved by the Institutional Review Board (IRB) at UC Davis (ID# 473010), and all participants gave informed consent.
: Not applicable.
: Dr Hessl has received funding from the following, all of which is directed to UC Davis, in support of fragile X syndrome treatment programs, and he receives no personal funds and has no relevant financial interest in any of the commercial entities listed: Autifony, Ovid, Tetra, Healx, and Zynerba pharmaceutical companies to consult on outcome measures and clinical trial design. RJH has received funding from Zynerba and the Azrieli foundation for treatment studies in Fragile X syndrome and unrelated to this study.
